LevelJump Closes Private Placement Raising Gross Proceeds of over $877,000
Toronto, Ontario--(Newsfile Corp. - July 4, 2022) - LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("LevelJump" or the...
Staff
wellteq Digital Health Inc. Announces Director Resignation
Vancouver, British Columbia--(Newsfile Corp. - July 4, 2022) - wellteq Digital Health Inc. (CSE: WTEQ) (OTCQB: WTEQF), (the "Company" or...
Emerald Health Therapeutics, Inc. Reports 2021 Year-End Results and Corporate Update
Company also provides bi-weekly MCTO status updateVancouver, British Columbia--(Newsfile Corp. - July 4, 2022) - Emerald Health Therapeutics, Inc. (CSE:...
Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
GENEVA, SWITZERLAND / ACCESSWIRE / July 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), announced...
Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk
GENEVA, SWITZERLAND / ACCESSWIRE / July 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a...
ALK spotlights the impact of respiratory allergies on children at EAACI Congress
Four leading experts in respiratory allergy spotlight the impact of respiratory allergy in children, in an ALK-sponsored symposium at the...
VIVO Cannabis Announces Results of 2022 AGM and Election of New Directors
Toronto, Ontario--(Newsfile Corp. - July 2, 2022) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) ("VIVO" or the "Company"), a...
Innovation Vista Named Most Promising Digital Transformation Firm
Los Angeles, California--(Newsfile Corp. - July 1, 2022) - CIO Review announces Innovation Vista as Most Promising Emerging Digital Transformation...
ClexBio Announces New Appointments to Board of Directors
OSLO, Norway & BOSTON--(BUSINESS WIRE)--ClexBio, an early-stage biotech company developing next-generation tissue engineered grafts for transplant, is announcing the appointment...
ProAssurance Second Quarter 2022 Results Release and Teleconference
BIRMINGHAM, Ala.--(BUSINESS WIRE)--ProAssurance Corporation (NYSE:PRA) will report results for the quarter ended June 30, 2022 after the close of normal...
Philips Signs Health Care Sector Pledge to Reduce Emissions as part of Department of Health and Human Services, White House Initiative
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the company has joined...
Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ET
Key Proposal #2 has received significant support, but additional votes are needed for approval Leading Independent Proxy Advisory Firms, ISS...
Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors
BOSTON and LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a...
Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting, Acute Treatment for Type 2 Diabetes
Biomea to present two oral abstracts across multiple animal models highlighting the ability of BMF-219, a covalent menin inhibitor, to...
GeneType Risk Assessment Test onboarding in 16 clinics
MELBOURNE, Australia, July 01, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HOUSTON, July 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for...
Results of Annual General Meeting
DUBLIN, Ireland, and Boston MA, July 1, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing...
BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat)
—Analysis from APeX-S showed 98 percent attack-free days during treatment with ORLADEYO after switching from an injectable therapy—RESEARCH TRIANGLE PARK,...
FibroGen to Participate at William Blair Biotech Focus Conference 2022
SAN FRANCISCO, July 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer,...
New Data Reinforce Efficacy of the UroLift® System for the Treatment of Enlarged Prostate
Presentations at the 37th Annual European Association of Urology Congress to Demonstrate Measurable and Sustained Improvement of BPH Symptoms and...